AAGPs™ were invented by Dr. Geraldine-Castelot-Deliencourt and developed and protected by patents in partnership with the Institute for Scientific Application (INSA) of France. For her work in this area Dr. Castelot-Deliencourt was honored in 2006 with France's highest award for scientific accomplishment - the Francinov Award.
ProtoKinetix is a bio-technology company that provides medical researchers with a platform for enhancing cell survival and health, both in vitro and in vivo.
At the heart of its technology is its patented anti-aging glycopeptide AAGP™. This small molecule (580 Daltons) displays abilities in resolving challenges confronting medical researchers in such areas as regenerative medicine and as a therapy for diseases relating to tissue inflammation and oxidation stress.
Because of its stability, small size and molecular makeup, it maintains its function in vivo without triggering the body's immune system. Further, it can function without toxic side effects common in treatments involving larger and less stable compounds.
These abilities are verified through testing in such areas as:
- Extension of stem cell harvesting, purification, expansion, cryopreservation and re-engraftment. See Test Results & Protocols > BioActivity Assays > "Effect of AAGP™ on Maintaining Stem Cell Number and Function in Mouse Neural Stem Cells During Cryopreservation." Also, "Effect of AAGP™ on Preserving Cell Survival Number in Human and Mouse Neural Stem Cells During Cryopreservation."
- Inflammation. See Test Results & Protocols > BioActivity Assays > "AAGP™ Reduces the Inflammatory Reaction (Cox-2 Induction) in Response to an Inflammatory Stimulus (Interleukin-1B)."
- Oxidation stress. See Test Results & Protocols > BioActivity Assays > "AAGP™ Protects Human Adult Fibroblasts Against Oxidation Stress (Hydrogen Peroxide and UVC) Induced Cell Death At 37°C."
- Diabetes treatment. See Test Results & Protocols > BioActivity Assays > "Affect of AAGP™ on the Functionality of Transplanted Islet Cells in a Diabetic Mouse Model."
Additional test results can be found in the Bioactivity section.
ProtoKinetix invites university and private research researchers to examine the properties of AAGP™ to determine how it can accelerate their development of a new generation of treatments, cures, and cell-survival solutions.
It should be noted that currently there is on-going independent research in such areas as uveitis and in monoclonal-antibody production.
AAGP™ is manufactured at facilities in North America, Europe, and Asia for shipment worldwide.
Interested parties please contact us to obtain AAGP™.